- Advertise
- Contact Editorial
- Editorial Submission Guidelines
- Contact MJH Life Sciences
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Pharmaceutical Executive-03-01-2019
Pharmaceutical Executive
Patient Advocacy: The Corporate Mandate
March 21, 2019
Features
39
3
Perspectives from big pharma and the rare disease space on how patient advocacy is evolving as a corporate function.
Patient Support Programs: Cost, Benefit, and Resourcing
March 18, 2019
Features
39
3
Working group explores the challenges of patient support programs (PSPs) and market research programs (MRPs) for pharmacovigilance (PV) professionals-and solutions currently being put into practice.
Patients is a Virtue
March 14, 2019
Features
39
3
Providers of patient service solutions for pharma companies share insights on the nuances of the "consumer' connection and the shifts taking place in making patient-centric programs and tools more alive for patients.
What Does Patient Centricity Look Like?
March 14, 2019
From the Editor
39
3
That often-muddled picture is becoming increasingly clearer in the patient and business context as different ways in which patients, patient communities, advocacy, and pharma engage each other converge.
John Crowley: Living the Mission
March 14, 2019
Features
39
3
Amicus Therapeutics CEO John Crowley, whose biotech journey and quest to cure two of his kids of a rare genetic disease is well chronicled, discusses the growing role of the patient-centered view in company culture-not just in adding “deeper meaning” to drug development, but in building patient advocacy into everyday business practice and strategy.
Research Bonds Strengthen
March 14, 2019
Features
39
3
Efforts to collaborate around patient engagement in every phase of product development are illustrating the growing relationship between disease advocacy groups and industry.
Parallel Trade a Victim of Brexit Collateral Damage
March 07, 2019
Columns
39
3
Despite a “temporary fix” at the ready, pharma supply repercussions loom if exit deal isn’t reached this month.
Multiple Pharma Issues Top Congressional Agenda
March 07, 2019
Columns
39
3
Wide-ranging probes to target marketing, pricing, and access.
Pharm Exec Joins MJH Portfolio
March 07, 2019
In the News
39
3
Michael J. Hennessy Jr., president of MJH Associates‚ Inc., answers questions about the acquisition of UBM Life Sciences media brands and his company’s perspective on the evolving biopharma landscape.
Cystic Fibrosis: The Importance of Patient Advocacy
March 06, 2019
Columns
39
3
The importance of patient advocacy in boosting research for cystic fibrosis.
Pinpointing Performance of Key Access Activities
March 06, 2019
Features
39
3
While market access functions have evolved, the same can’t be said for measures used to gauge the contribution of these activities on overall business. To that end, an industry working group has developed a common framework focused on the most relevant access performance metrics (APMs).
The Path to Patient-Focused Accountability
March 01, 2019
Features
39
3
Benchmark survey assesses the industry’s progress so far in moving from words to action in its approach to patient centricity.
Pharmaceutical Executive, March 2019 Issue (PDF)
March 01, 2019
Issue PDF
39
3
Click the title above to open the Pharmaceutical Executive March 2019 issue in an interactive PDF format.
Country Report: France
March 01, 2019
Special Sponsored Section
39
3
After a prolonged period of relative stagnation, the strategically influential, clinically rich French life sciences market suddenly seems to be rediscovering its mojo-thrusting the pharma and medtech sectors into the spotlight.